JP2021521850A5 - - Google Patents

Info

Publication number
JP2021521850A5
JP2021521850A5 JP2020560340A JP2020560340A JP2021521850A5 JP 2021521850 A5 JP2021521850 A5 JP 2021521850A5 JP 2020560340 A JP2020560340 A JP 2020560340A JP 2020560340 A JP2020560340 A JP 2020560340A JP 2021521850 A5 JP2021521850 A5 JP 2021521850A5
Authority
JP
Japan
Prior art keywords
nuclease
cells
nucleotide sequence
vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028858 external-priority patent/WO2019209912A2/en
Publication of JP2021521850A publication Critical patent/JP2021521850A/ja
Publication of JP2021521850A5 publication Critical patent/JP2021521850A5/ja
Pending legal-status Critical Current

Links

JP2020560340A 2018-04-27 2019-04-24 Ｘ連鎖性高ＩｇＭ症候群のゲノム編集治療 Pending JP2021521850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663485P 2018-04-27 2018-04-27
US62/663,485 2018-04-27
PCT/US2019/028858 WO2019209912A2 (en) 2018-04-27 2019-04-24 Therapeutic genome editing in x-linked hyper igm syndrome

Publications (2)

Publication Number Publication Date
JP2021521850A JP2021521850A (ja) 2021-08-30
JP2021521850A5 true JP2021521850A5 (https=) 2023-03-30

Family

ID=68295746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560340A Pending JP2021521850A (ja) 2018-04-27 2019-04-24 Ｘ連鎖性高ＩｇＭ症候群のゲノム編集治療

Country Status (8)

Country Link
US (1) US20210324381A1 (https=)
EP (1) EP3784292A4 (https=)
JP (1) JP2021521850A (https=)
KR (1) KR20210005178A (https=)
CN (1) CN112312931A (https=)
AU (1) AU2019261385A1 (https=)
CA (1) CA3098489A1 (https=)
WO (1) WO2019209912A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060570A1 (en) 2017-04-21 2018-10-25 Seattle Children's Hospital (Dba Seattle Children's Research Institute Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US20230158110A1 (en) * 2018-05-30 2023-05-25 The Regents Of The University Of California Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked hyper-igm syndrome (xhim)
WO2025073293A1 (en) * 2023-10-02 2025-04-10 Consorcio Centro De Investigación Biomédica En Red Gene editing methods for cd34+ cells to achieve clinically relevant efficacies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4102099A (en) * 1998-05-29 1999-12-13 Heska Corporation Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
PL3360964T3 (pl) * 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
EP3289080B1 (en) * 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
US10179918B2 (en) * 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2985650A1 (en) * 2015-05-13 2016-11-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Enhancing endonuclease based gene editing in primary cells
WO2018035387A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3535396A1 (en) * 2016-11-01 2019-09-11 Novartis AG Methods and compositions for enhancing gene editing
GB201618414D0 (en) * 2016-11-01 2016-12-14 Patterson James Regulated cell lines and methods of use thereof
WO2018206577A1 (en) * 2017-05-10 2018-11-15 Aarhus Universitet Interferon primed plasmacytoid dendritic cells
MA50833A (fr) * 2017-10-17 2020-08-26 Bayer Healthcare Llc Compositions et méthodes pour l'édition génique pour l'hémophilie a
DK3701028T3 (da) * 2017-10-24 2024-11-11 Editas Medicine Inc Systemer og fremgangsmåder til behandling af hyper-igm-syndrom
US20200263206A1 (en) * 2017-11-07 2020-08-20 Editas Medicine, Inc. Targeted integration systems and methods for the treatment of hemoglobinopathies
AU2018370217A1 (en) * 2017-11-17 2020-05-28 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating Cytokine Release Syndrome

Similar Documents

Publication Publication Date Title
JP2021521850A5 (https=)
JP7252328B2 (ja) Ｒｎａを編集する方法および組成物
JP7396783B2 (ja) 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
JP2024073596A5 (https=)
JP2026064992A (ja) β異常ヘモグロビン症を治療するためのＣＲＩＳＰＲ／ＣＡＳ関連方法および組成物
Canver et al. Customizing the genome as therapy for the β-hemoglobinopathies
JP2021521855A5 (https=)
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
JP2016500262A5 (https=)
JP2019524140A5 (https=)
CN105331608A (zh) 脑膜炎双球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
JP2015533786A5 (https=)
JP2016504026A5 (https=)
JP2019508051A5 (https=)
CN105400779A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CCR5基因的靶序列和sgRNA及其应用
JP2021522858A5 (https=)
JP2020517270A5 (https=)
WO2021083183A1 (zh) 一种造血干细胞hbb基因修复的方法及产品
FI3615674T3 (fi) Menetelmiä reumatoidin artriitin hoitoon HLA-geenin RNA-ohjattua genomin muokkausta käyttämällä
Osamu et al. A rat brain-derived neurotrophic factor-encoding gene generates multiple transcripts through alternative use of 5′ exons and polyadenylation sites
JP2020517289A5 (https=)
JP2022033728A (ja) 改変細胞、調製方法、及び構築物
CN110577969B (zh) CRISPR/Sa-SlugCas9基因编辑系统及其应用
CN110499334A (zh) CRISPR/SlugCas9基因编辑系统及其应用
WO2020043869A3 (en) Methods and compositions for producing a virus